Cagrilintide
Also known as: NN9838
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk. It is investigational and not FDA-approved; Novo Nordisk's lead development path is the CagriSema co-formulation with semaglutide for weight management. Monotherapy cagrilintide was evaluated in Phase 2 but was deprioritized in favor of the combination.
Pricing for Cagrilintide
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
Average price
$13.60/mg
range $2.00–$40.00/mg
Sellers
64
from $0.00
45-day trend
+0.5%
vs 45-day avg $/mg
56 of 64 sellers have a current price· 38 stale listings hidden (not seen in 7 days)
Top Merit pick
🇺🇸 Peptide Partners99via Disclosed Labs · just now
$5.25/mg -61.4% vs avg$1050
200mg
- 🇺🇸 Glacier Aminos99
✓ verified at source · just now
$5.70/mg -58.1% vs avg$56.99
10mg
- 🇺🇸 Moglabs96
via Disclosed Labs · just now
$8.20/mg -39.7% vs avg$82.00
10mg
no purity 1 COA - 🇺🇸 BioLongevity Labs96
via Disclosed Labs · just now
$34.00/mg +149.9% vs avg$170
5mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · just now
$9.80/mg -28% vs avg$98.00
10mg
- 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · just now
$10.00/mg -26.5% vs avg$99.99
10mg
99.9% purity 1 COA - 🇺🇸 Licensed Peptides95
✓ verified at source · just now
$10.80/mg -20.6% vs avg$108
10mg
- 🇺🇸 Peptide Plugs89
✓ verified at source · just now
$6.00/mg -55.9% vs avg$60.00
10mg
99.9% purity 1 COA - 🇺🇸 Simple Peptide85
via Disclosed Labs · just now
$14.00/mg +2.9% vs avg$140
10mg
- Peptide Supply Co.83
via Disclosed Labs · just now
$4.35/mg -68% vs avg$435
100mg
- 🇨🇳 Reta Peptide83
✓ verified at source · just now
$13.50/mg -0.8% vs avg$135
10mg
99.3% purity 8 COAs - 🇺🇸 Certified Peptides62
✓ verified at source · just now
$12.80/mg -5.9% vs avg$128
10mg
no purity 2 COAs - 🇭🇰 Hkuppeptide50
✓ verified at source · just now
$2.00/mg -85.3% vs avg$10.00
5mg
no purity - 🇭🇰 zztai Peptide Ltd43
✓ verified at source · just now
$18.00/mg +32.3% vs avg$180
10mg
no purity - peptidetech.isUnscored
via Disclosed Labs · just now
$6.00/mg -55.9% vs avg$59.99
10mg
no purity - 🇺🇸 NG PeptideUnscored
via Disclosed Labs · just now
$6.50/mg -52.2% vs avg$65.00
10mg
no purity - optimasupply.isUnscored
via Disclosed Labs · just now
$20.00/mg +47% vs avg$100
5mg
no purity - realpeptides.coUnscored
via Disclosed Labs · just now
$32.50/mg +138.9% vs avg$325
10mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
COAs for Cagrilintide
119 third-party tests across 23 vendors. Each card links to the full report.
For
Cagrilintide
by EZ Peptides· batch EZP-CAG1006162026-02
For
Cagrilintide
by Ion Peptide· batch CGL5-06172026
For
Cagrilintide 10
by EZ Peptides· batch EZP-CAG10061620226-02
For
Cagrilintide
by Ion Peptide· batch CGL10-06252026
For
Cagrilintide
by Ion Peptide· batch CGL5-06242026
For
Cagrilintide
by Optima Supply· batch OS-2026-2806
For
Cagrilintide
by Hydro Research Peptides· batch HR-2026-3852
For
Cagrilintide
by EZ Peptides· batch EZP-CAG0505152026-12
For
Cagrilintide
by EZ Peptides· batch EZP-CAG0505152026-12
For
Cagrilintide 5mg
by EZ Peptides· batch EZP-CAG05051520226-12
For
Cagrilintide
by Nox Amino· batch NA-CG0526-01
For
Cagrilintide
by Peptide Partners· batch SPL-3792
For
Cagrilintide
by NG Peptide· batch CG10-12
For
Cagrilintide
by Crush Research· batch CRCAG-5-2604-1
For
Cagrilintide
by Peptide Partners· batch CG202603
For
Cagrilintide
by Qihang Peptide· batch 4
For
Cagrilintide
by Amino Club· batch CAG0001
For
Cagrilintide
by Glacier Aminos· batch CAG5GA-02
For
Cagrilintide
by Ion Peptide· batch CAC10-03192026
For
Cagrliintide
by Ion Peptide· batch CAG10-03192026
For
Cagrilintide
by Mile High Compounds· batch CAG-010-MH-02
For
Cagrilintide
by Licensed Peptides· batch 032520261
For
Cagrilintide
by Pepsgpt· batch P-1457978-P
For
Cagrilintide
by EZ Peptides· batch EZP-CAG0502262026-11
20 citations indexed for Cagrilintide
cohort · 2026
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials
Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.
Study · 2026
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study
Background Cagrilintide-semaglutide (CagriSema) is a novel, once-weekly combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.
rct · 2026
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Background Basal insulin treatment for type 2 diabetes often results in inadequate glycaemic control and is associated with weight gain and increased risk of hypoglycaemia.
Study · 2026
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
Background The amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide have complementary effects on glycaemic control and bodyweight.
Study · 2026
Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide
Background and objectives Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management and as a fixed-dose combination with the glucagon-like peptide-1 receptor agonist semaglutide (CagriSema) for weight management and treatment of type 2 diabetes.
review · 2026
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis
Background Obesity is a global health challenge associated with substantial cardiometabolic morbidity. Cagrilintide, a long-acting amylin analogue, alone or in combination with semaglutide (CagriSema), has emerged as a novel pharmacologic strategy for weight management.